CHAPTER 87 DIGITALIS TOXICITY AND DIGOXIN IMMUNE FAB

Treatment of 150 Cases of Life-Threatening Digitalis Intoxication With Digoxin-specific Fab Antibody Fragments: Final Report of a Multicenter Study

Antman EM, Wenger TL, Butler VP Jr, Haber E, Smith TW. Circulation. 1990;81(6):1744–1752

BACKGROUND

The effects of digitalis toxicity can be life-threatening, and include lethal arrhythmias such as AV block and ventricular tachycardia. Although the use of digoxin-specific antibody (Fab) fragments to treat digoxin toxicity was first described in 1976, at the time of this study Fab had not been tested across a broad set of patients, and adequate safety information for drug approval had not yet been obtained. Today, the antidote is marketed under the trade names DigiFab and Digibind.

OBJECTIVES

To determine the ability of Fab fragments to reverse the toxic effects of digitalis, and to assess its safety.

METHODS

Open-label multicenter clinical trial conducted in 21 centers between 1974 and 1986.

Participants

Related posts:

Oral vs. IV Rehydration Spontaneous Ureteral Stone Passage Heparinizing Unstable Angina Amiodarone in Ventricular Fibrillation Bicarbonate Therapy in DKA CT Before Lumbar Puncture in Meningitis

Stay updated, free articles. Join our Telegram channel

Join